The United Laboratories International Holdings Limited (HKG:3933)

Market Cap	15.67B -36.1%
Revenue (ttm)	13.69B -15.9%
Net Income	622.53M -82.4%
EPS	0.32 -83.7%
Shares Out	1.97B
PE Ratio	25.08
Forward PE	12.32
Dividend	0.30 (3.76%)
Ex-Dividend Date	Jul 7, 2026

Volume	7,054,400
Open	7.55
Previous Close	7.80
Day's Range	7.55 - 7.97
52-Week Range	6.67 - 13.72
Beta	0.28
Analysts	Buy
Price Target	11.98 (+50.6%)
Est. Earnings	Dec 1, 2026

About HKG:3933

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers amoxicillin products; insulin series, antibiotics, and ophthalmic products; and veterinary drugs. It also provides 6-aminopenicillanic acid and penicillin G potassium products. In addition, the company provides endocrine and metabolism, anti-...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 18,000
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3933

Financial Performance

In 2025, HKG:3933's revenue was 13.21 billion, a decrease of -3.99% compared to the previous year's 13.76 billion. Earnings were 2.09 billion, a decrease of -21.57%.

Financial numbers in CNY

Analyst Summary

According to 9 analysts, the average rating for 3933 stock is "Buy." The 12-month stock price target is $11.98, which is an increase of 50.60% from the latest price.

Price Target

$11.98

(50.60% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error